[Form 4/A] GeneDx Holdings Corp. Amended Insider Trading Activity

Rhea-AI Filing Summary

Kevin Feeley, the Chief Financial Officer of GeneDx Holdings Corp. amended a Form 4 to correct a typographical error and to report the vesting and acquisition of restricted stock units. The amendment clarifies that on 09/16/2025 Mr. Feeley acquired 7,197 restricted stock units, each convertible into one share of Class A common stock for no consideration, increasing his beneficial ownership to 12,483 shares.

The filing notes the original Form 4 filed on 09/18/2025 incorrectly showed a disposition code where an acquisition code was intended; no other line items were changed. The amendment is signed by an attorney-in-fact on behalf of the reporting person.

Positive

• Correction of disclosure improves regulatory accuracy by aligning the transaction code with the actual RSU vesting event.
• Insider acquisition of 7,197 RSUs increases the reporting person’s beneficial ownership to 12,483 shares, reflecting insider alignment with the company.

Negative

• None.

Insights

Securities Analyst

TL;DR: Amendment corrects a clerical error and confirms an acquisition of 7,197 RSUs, modestly increasing insider ownership.

The amendment does not introduce new economic events beyond the previously disclosed RSU vesting on 09/16/2025. It clarifies the transaction code as an acquisition, which aligns the record with the underlying vesting event and the reported post-transaction beneficial ownership of 12,483 Class A shares. For investors, this is an administrative correction rather than a change in economic exposure. The transaction price is reported as $0, consistent with RSU settlement mechanics.

Corporate Governance Expert

TL;DR: Correction improves disclosure accuracy; no substantive governance concern evident from the amendment.

The amendment addresses a typographical error in the original Form 4 where a disposition code was mistakenly used. Accurate Section 16 reporting is important for transparency; correcting the code to acquisition ensures regulatory records match the actual vesting event and beneficial ownership schedule. The filing was executed via attorney-in-fact, which is common practice for insiders and is properly signed.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Feeley Kevin

(Last) (First) (Middle)

C/O GENEDX HOLDINGS CORP.

333 LUDLOW ST, NORTH TOWER, 6TH FLOOR

(Street)

STAMFORD CT 06902

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
GeneDx Holdings Corp. [ WGS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF FINANCIAL OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
09/16/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)
09/18/2025

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	09/16/2025		M		7,197	A	$0(1)	12,483	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration.

Remarks:

The Form 4 filed on September 18, 2025 to report the reporting person's vesting of restricted stock units on September 16, 2025 is amended herein to correct a typographical error in column 4 of Table I. The correct code for the transaction is a code "A" for acquisition, consistent with the disclosure in the row. The Form inadvertently set forth a code "D" in column 4 of this row when originally filed. The line item of the Form 4 remains otherwise unmodified.

	/s/ Bridget Brown, Attorney-in-Fact	09/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did the amended Form 4 for GeneDx (WGSWW) change?

The amendment corrected a typographical error in Table I: the transaction code for the 09/16/2025 vesting was changed to A (acquisition) from an incorrect D (disposition); no other changes were made.

How many restricted stock units did the reporting person acquire?

The reporting person acquired 7,197 restricted stock units on 09/16/2025, each representing a contingent right to one share upon settlement for no consideration.

What is the reporting person’s beneficial ownership after the transaction?

Following the reported acquisition, the reporting person beneficially owns 12,483 shares of Class A common stock.

Who filed the Form 4 amendment and when was it signed?

The Form 4 amendment was filed to correct the original 09/18/2025 filing for the 09/16/2025 transaction and was signed by Bridget Brown, Attorney-in-Fact on 09/18/2025.

What does the price of $0 mean for the RSUs reported?

The reported price of $0 indicates the RSUs vest and convert into shares upon settlement without additional cash payment by the reporting person.